# A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

> **NCT02383368** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Lymphoma
- Refractory Solid Tumors
- Advanced Cancer

## Interventions

- **DRUG:** ASP4132

## Key facts

- **NCT ID:** NCT02383368
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-23
- **Primary completion:** 2018-04-27
- **Final completion:** 2018-04-27
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02383368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02383368, "A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02383368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*